Company intelligence / Profile preview

Speranza Therapeutics

Ownership: Private
Development stage: Phase 1

Overview

The S.T. Genesis is an FDA-cleared, noninvasive percutaneous nerve field stimulator applied to the outer ear to reduce symptoms of opioid withdrawal by targeting brain areas involved in pain and anxiety. It provides treatment over five days during acute detoxification and aims to facilitate transition into longer-term addiction care.

Therapeutic areas: Psychiatry
Modalities: Medical device (Percutaneous Nerve Field Stimulator)Noninvasive neuromodulationNot a drug/biologic company; focus is on device-based therapy for opioid withdrawal.
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Prime-2-CoV_Beta

Phase 1

Indications: COVID-19

Partnerships

No major pharma or biotech partnerships disclosed.

Beyond the preview

Go deeper on Speranza Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Speranza Therapeutics.

Explore the full profile